PMID- 30873649
OWN - NLM
STAT- MEDLINE
DCOM- 20200102
LR  - 20200102
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 33
IP  - 6
DP  - 2019 Jun
TI  - Laser treatment of hyperpigmented lesions: position statement of the European 
      Society of Laser in Dermatology.
PG  - 987-1005
LID - 10.1111/jdv.15497 [doi]
AB  - BACKGROUND: Lasers and intense pulsed light sources (IPLS) are proposed for the 
      treatment of many pigmentary disorders. They are sometimes considered as magic 
      tools able to remove any type of lesions. Although being the best option for 
      several hyperpigmented lesions, they can also worsen some conditions and have 
      potential side-effects. OBJECTIVE: The aim of this review was to give 
      evidence-based recommendations for the use of lasers and IPLS in the treatment of 
      hyperpigmented lesions. METHODS: These recommendations were produced for the 
      European Society of Laser Dermatology by a consensus panel made up of experts in 
      the field of pigment laser surgery. Recommendations on the use of lasers and 
      light treatments were made based on the quality of evidence for efficacy, safety, 
      tolerability, cosmetic outcome, patient satisfaction/preference and, where 
      appropriate, on the experts' opinion. RESULTS: Lasers and IPLS are very effective 
      for treating many hyperpigmented lesions such as lentigos, dermal 
      hypermelanocytosis or heavy metal depositions. In the other hand, they have to be 
      considered with great caution for other disorders, such as cafe au lait macules, 
      melasma or postinflammatory hyperpigmentation. After making the correct 
      diagnosis, if lasers or IPLS are indicated, the optimal wavelengths and 
      parameters will be chosen taking into account the skin phototype, origin and 
      depth of the target pigments. CONCLUSION: Although potentially very effective, 
      lasers and IPLS cannot be proposed for all types of hyperpigmented lesions. In 
      all cases, precise recognition of the disorder is mandatory for choosing between 
      these devices and other therapeutic approaches.
CI  - (c) 2019 European Academy of Dermatology and Venereology.
FAU - Passeron, T
AU  - Passeron T
AUID- ORCID: 0000-0002-0797-6570
AD  - Department of Dermatology, Centre Hospitalier Universitaire Nice, Universite Cote 
      d'Azur, Nice, France.
AD  - INSERM U1065, Team 12, C3M, Universite Cote d'Azur, Nice, France.
FAU - Genedy, R
AU  - Genedy R
AD  - Faculty of Medicine, Department of Dermatology, Alexandria University, 
      Alexandria, Egypt.
FAU - Salah, L
AU  - Salah L
AD  - Ministry of Health, Jeddah, Saudi Arabia.
FAU - Fusade, T
AU  - Fusade T
AD  - Laser Clinical Center, Paris, France.
FAU - Kositratna, G
AU  - Kositratna G
AD  - Department of Dermatology, Massachusetts General Hospital, Harvard Medical 
      School, Boston, MA, USA.
FAU - Laubach, H-J
AU  - Laubach HJ
AD  - Department of Dermatology, Hopitaux Universitaires de Geneve, Geneva, 
      Switzerland.
FAU - Marini, L
AU  - Marini L
AD  - The Skin Doctors Center, Trieste, Italy.
FAU - Badawi, A
AU  - Badawi A
AD  - National Institute of Laser Enhanced Sciences, Cairo University, Giza, Egypt.
AD  - Department of Dermatology, Faculty of Medicine, University of Szeged, Szeged, 
      Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190314
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
SB  - IM
MH  - Europe
MH  - Humans
MH  - Hyperpigmentation/*therapy
MH  - *Laser Therapy
MH  - Practice Guidelines as Topic
MH  - Skin/pathology
EDAT- 2019/03/16 06:00
MHDA- 2020/01/03 06:00
CRDT- 2019/03/16 06:00
PHST- 2018/06/08 00:00 [received]
PHST- 2019/01/14 00:00 [accepted]
PHST- 2019/03/16 06:00 [pubmed]
PHST- 2020/01/03 06:00 [medline]
PHST- 2019/03/16 06:00 [entrez]
AID - 10.1111/jdv.15497 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2019 Jun;33(6):987-1005. doi: 10.1111/jdv.15497. 
      Epub 2019 Mar 14.